Penile cancer is rare, driven partly by HPV, and dangerous when caught late

Penile cancer is a rare disease: in high-income countries it affects roughly 0.1 to 1 man in every 100,000, though in parts of Africa, Asia and South America it can account for up to 10% of male cancers [s1]. Most cases are squamous cell carcinomas, and about half carry the DNA of human papillomavirus (HPV) — the same virus behind most cervical cancer — which is why the vaccine that prevents cervical disease should prevent some penile cancers too [s1][s2]. The danger lies less in the primary tumour than in how early the cancer spreads to the lymph nodes of the groin [s1].

The established risk factors are consistent across studies: the absence of circumcision in childhood, phimosis (a foreskin too tight to retract fully), chronic inflammation, poor penile hygiene, smoking, immunosuppression and HPV infection [s1]. The protective association is specifically with circumcision performed in childhood, well before the exposures that drive the cancer, and the moisture and persistent inflammation trapped under a non-retractile foreskin appear to be part of why [s1]. None of these is a guarantee in either direction — the cancer is rare enough that most men with a risk factor never develop it — but together they describe who is more likely to.

Two diseases wearing one name

How large the viral contribution is has been pinned down. A 2019 systematic review and meta-analysis pooled 52 studies and 4,199 penile cancers and found HPV DNA in 50.8% (95% CI 44.8–56.7) [s2]. That share is far from uniform across tumour types: HPV was present in 84.0% (71.0–93.6) of basaloid squamous carcinomas and 75.7% (70.1–81.0) of warty-basaloid tumours, but in a minority of the commoner keratinising cancers, with HPV16 the predominant type [s2]. The split matters because it means penile cancer is really two overlapping diseases — one virus-driven, one not — with different biology, and it is the reason a preventive vaccine can only ever address part of the burden [s1][s2]. The same review also gauged p16INK4a, a protein whose over-expression marks transcriptionally active HPV and which pathologists use to sort virus-driven tumours from the rest [s2]. That sorting is not academic: the two groups carry different prognostic profiles, and separating them is now part of how the disease is classified and studied [s1].

Staging the groin decides the outcome

Localised disease can often be handled with organ-sparing treatment — topical therapy, limited surgery or radiotherapy — rather than amputation, and current guidance pushes toward preserving as much of the penis as the cancer allows [s1][s3]. The harder problem sits in the groin. Because penile cancer spreads early through the lymphatics and imaging cannot reliably detect microscopic disease, correctly staging the inguinal lymph nodes upfront — surgically, in men whose tumours carry that risk — is the single step that most shapes survival [s1][s3]. Survival tracks closely with whether, and how far, the cancer has reached those nodes, which is why guidelines treat early nodal staging as decisive rather than optional [s1]. Advanced disease requires multimodal treatment built around cisplatin-based chemotherapy, and the optimal sequence of treatments and the right patients for each are still being investigated [s1].

Prevention and the cost of delay

For prevention, the levers are the risk factors themselves. HPV vaccination, given before exposure, targets the viral half of the disease, and guideline bodies now weigh its role in boys as well as girls [s3] — the same logic that drives HPV vaccination against cervical cancer. Beyond that, the practical message is unglamorous: a persistent sore, lump, colour change or non-healing lesion on the penis warrants prompt assessment, because outcomes hinge on catching the cancer before it reaches the groin [s1].

Delay is the recurring theme in poor outcomes. The disease is rare, awkward to raise and easily mistaken for an infection, so men often wait — and a cancer defined by early lymphatic spread is exactly the kind that punishes waiting [s1]. As with testicular cancer in young men, there is no population screening programme for a tumour this uncommon; the realistic safeguard is that an unfamiliar, persistent change gets looked at rather than left, and that the men most exposed to HPV-related cancers are reached by vaccination before the virus ever takes hold.